Therapeutic angiogenesis for severe ischemic heart diseases by autologous bone marrow cells transplantation.
Conventional therapies for severe ischemic heart disease are limited in applicability. While several angiogenesis researches have shown novel efficacy, safety and feasibility for clinical use, recently we have started the clinical trial of a sole cell therapy using autologous bone marrow mononuclear cells transplantation targeted into ischemic hibernating myocardium. Here, we review the background of bone marrow cell research and introduce therapeutic angiogenesis for severe ischemic heart disease by autologous bone marrow cells transplantation.
Hattori
Reiji
R
Department of Cardiothoracic Surgery, Institut Jantung Negara (National Heart Institute), 145, Jalan Tun Razak, 50400 Kuala Lumpur, Malaysia. reijih@attglobal.net
Matsubara
Hiroaki
H
D000368:Aged; D000818:Animals; D016026:Bone Marrow Transplantation / Q000379:methods*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D008954:Models, Biological; D017202:Myocardial Ischemia; D018919:Neovascularization, Physiologic; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome